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Observational studies suggest childhood externalising disorders are associated with 
increased smoking and early age of initiation. However, causality cannot be inferred from 
observational data alone. The current study uses two-sample MR to examine the causal 
relationship between externalising behaviours and tobacco use. 
Single nucleotide polymorphisms (SNPs) associated with aggression were obtained from 
The Early Life Epidemiology Consortium (mean age 8 years), ADHD from The Integrative 
Psychiatric Research and Psychiatrics Genomics Consortium (age range 6 to 18 years), and 
tobacco initiation and age of onset from The Tobacco and Genetics Consortium. SNPs were 
combined using inverse variance weighted approach, weighted median approach, and MR-
Egger regression.  
There was no clear evidence of an effect of aggression on tobacco initiation or age of onset 
for either childhood aggression (initiation:  -0.002, 95% CI -0.005, 0.001, P=0.286; age:  -
0.001 95% CI -0.002, 0.000, P=0.310) or adolescent aggression (initiation:  -0.001, 95% CI 
-0.006, 0.003, P=0.610; age:  0.000, 95% CI 0.000, 0.001, P=0.183)]. However, there was 
some evidence of an association of ADHD on tobacco initiation (OR 1.23, 95% CI 1.10, 1.35, 
P = 0.016), although no clear evidence of an effect of ADHD on age of onset (OR= 1.022, 
95% CI 0.992, 1.052, P=0.215). 
Our results provide some evidence that genetic risk of childhood ADHD is causally related to 
increased risk of tobacco initiation; however, the causal estimate is relatively small. We 
found no clear evidence that genetic risk of childhood aggression is causally related to risk of 
tobacco initiation or age of onset. 
  
Investigating possible causal associations of externalising behaviours and tobacco initiation: 
A Mendelian randomisation analysis 
 
Introduction 
 Externalising disorders such as conduct disorder (CD) and attention-deficit 
hyperactivity disorder (ADHD) are characterised by behaviours including aggressiveness, 
impulsivity, sensation seeking, and often criminal behaviour at older ages (Brazil et al., 2016, 
Goldstein et al., 2017, Holmes et al., 2001). Externalising disorders are strongly associated 
with substance use, including tobacco use (Brook et al., 2014, Kim et al., 2009, Brook et al., 
2010), and externalising behaviours or symptoms below a clinical threshold are similarly 
associated with increased risk of smoking (Kollins et al., 2005). Individuals with externalising 
disorders have similar rates of smoking as other psychiatric disorders (~>40%), experience 
higher rates of smoking, earlier onset of smoking, and greater nicotine dependency 
(Pomerleau et al., 1995, John et al., 2004, Lasser et al., 2000, Bagot et al., 2007).  
Externalising disorders are associated with deficits in reward function – reduced sensitivity to 
favourable stimuli and increased reward sensitivity. (Verdejo-Garcia et al., 2008). For 
example, ADHD is characterised by abnormal functioning of the striatal dopaminergic 
system and disruptions in dopaminergic transmission within corticostriatal circuits, resulting 
in executive functioning deficits (McClernon and Kollins, 2008, Solanto, 1998). These 
individuals display decreased dopamine (DA) tone from below-normal presynaptic activation 
of DA autoreceptors resulting in exaggerated DA release to salient stimuli (McClernon and 
Kollins, 2008). In both clinical and preclinical studies nicotine is shown to stimulate striatal 
DA release, suggesting nicotine-stimulated DA release may be more rewarding in individuals 
with ADHD (McClernon and Kollins, 2008, Corrigall et al., 1994, Brody et al., 2004).  
Therefore, individuals with ADHD may find higher levels of reward reinforcement from initial 
tobacco use, which may in turn facilitate the transition to continued use (McClernon and 
Kollins, 2008). 
Additionally, externalising disorders are characterised by impulsive behaviour 
(behaviour that lacks foresight, evaluation, and inhibitory control). These individuals typically 
prefer immediate rewards (over possible larger rewards in the future) (Verdejo-Garcia et al., 
2008). Therefore, impulsivity may lead individuals to choose rewarding stimuli despite the 
possibility of negative outcomes. A hypersensitive reward system may predispose 
individuals to early-onset substance use or mediate the transition from experimental to more 
frequent/ daily use (Aklin et al., 2009). Animal studies have supported this hypothesis, as 
rodents divided into ‘high-impulsivity’ and ‘low impulsivity’ groups based on attentional tasks 
show differential response to drug self-administration. High-impulsive displayed more rapid 
acquisition and higher rates of drug self-administration in response to decreased levels of 
dopamine D2-receptor binding (Dalley et al., 2007). These findings are mirrored in human 
PET studies where decreased striatum D2-receptor density is observed in addicted 
individuals, resulting in increased positive psychological and physiological response to initial 
drug exposure (Volkow et al., 1993, Volkow et al., 1996, Wang et al., 1996).  
 Tobacco may also be used for self-medication in individuals with ADHD to alleviate 
ADHD symptoms through negative reinforcement (Laucht et al., 2007, Rodriguez et al., 
2008). Studies using transdermal nicotine patches alongside stimulant medicine have 
displayed increased attention capabilities in adult ADHD patients (Gehricke et al., 2006). 
Furthermore, studies using nicotine patches in non-smoking ADHD patients have displayed 
increases in attention and cognition similar to methylphenidate (Potter and Newhouse, 
2004), improved behavioural inhabitation  (Potter and Newhouse, 2004) and increased 
positive affect (Levin et al., 1996, Rodriguez et al., 2008, McClernon and Kollins, 2008).  
However, the causal nature of this relationship, and the direction of causality, remain 
unclear. Evidence from longitudinal studies suggests that externalising behaviours in 
children are associated with subsequent early onset tobacco use (Korhonen et al., 2010, 
Brook et al., 2010, Crone and Reijneveld, 2007, Audrain-McGovern et al., 2004), and while 
reverse causality is unlikely in this context due to the onset of externalising disorders in 
young children (prior to average smoking initiation ~age 15), residual confounding may still 
be operating (e.g. via intrauterine tobacco exposure). Experimental studies are typically 
impossible in substance use research for long-term outcomes for obvious ethical and 
practical reasons. While we can examine the association between externalising behaviours 
and tobacco use in observational studies, these have provided conflicting evidence on the 
temporal direction of association (Korhonen et al., 2010, Cadoret et al., 1983, Brook et al., 
2010, Crone and Reijneveld, 2007, Hicks et al., 2009). Ultimately, however, conventional 
epidemiological methods using observational data cannot support strong causal inference as 
problems such as selection bias, reverse causation, and residual confounding are inherent in 
observational data (Davey Smith and Ebrahim, 2001). It is therefore important to consider 
alternative methods to support stronger causal inference, such as the use of negative 
controls, cross-contextual designs, and instrumental variable analysis (Gage et al., 2016b). 
One type of instrumental variable analysis is Mendelian randomisation (MR), in which 
genetic variants robustly predicting an exposure of interest are used as an unconfounded 
proxy for that exposure. Therefore, any associations found between these genetic variants 
and the outcome provide evidence of a casual effect of the exposure captured by the genetic 
variants on the outcome, without the risk of reverse causation or confounding. Two-sample 
MR uses variant-exposure associations identified via genome-wide association studies 
(GWAS) , and variant-outcome associations from another independent GWAS, using 
publicly-available summary data (Burgess et al., 2015). The current study uses two-sample 
MR to examine the causal relationship between externalising behaviours and tobacco 
initiation (Bowden et al., 2015).To compare across the spectrum of externalising disorders 




For our externalising behaviours exposure we used summary data from the Early Life 
Epidemiology Consortium (EAGLE) consortium GWAS of aggressive behaviour on a sample 
of 18,988 individuals. Aggression was measured using continuous study-specific scales 
(Pappa et al., 2016). Six SNPs were identified as the top SNPs approaching genomewide 
significance (P < 5 x 10-5) for aggression. The GWAS further identified top SNPs stratified by 
age group, with five SNPs approaching genomewide significance for early childhood (mean 
age 5.36 years, SD 1.5), and six SNPs for middle childhood/early adolescence (mean age 
11.39 years, SD 1.86) (see Supplementary Table S1).  
For our ADHD exposure we used summary data from the Initiative for Integrative 
Psychiatric Research (iPSYCH) and Psychiatrics Genomics Consortium (PGC) GWAS of 
ADHD on 55,354 individuals (ages 6 to 19) (Demontis et al., 2017). ADHD was measured 
using binary cohort-specific diagnosis of ADHD. Fourteen independent SNPs (were 
identified as genomewide significant (P < 5 x 10-8) (see Supplementary Table S2).  
Outcome measures 
For our tobacco initiation outcome we used summary data from the Tobacco and 
Genetics Consortium (TAG) GWAS of smoking behaviour (Tobacco and Genetics, 2010). 
Tobacco initiation (n = 74,053) was a binary ever/never measure and age of initiation (n = 
24,114) was the reported age at which participants started smoking. 
 
Statistical analyses 
 SNPs associated with aggression and ADHD were identified in their respective 
GWAS and subsequently extracted from the tobacco GWAS (see Supplementary Tables S1-
S2). Where original SNPs were unavailable, proxy SNPs were identified using SNiPA 
(http://snipa.helmholtz-muenchen.de/snipa3/) with an r2 threshold of  0.9. SNP-exposure 
and SNP-outcome associations were combined using an inverse-variance weighted 
approach (IVW), weighted median approach, and MR-Egger regression. Here, we use 
multiple methods, each with differing underlying assumptions regarding instrument validity, 
to triangulate our results (Lawlor et al., 2016). IVW weights regression of SNP-exposure and 
SNP-outcome coefficients restricting the intercept to zero, and assumes all instruments are 
valid with no pleiotropy (Burgess et al., 2013). Weighed median provides a causal estimate if 
at least 50% of the instruments are valid (Mostafavi, 2016). MR-Egger uses an intercept 
coefficient in the weighted regression to relax the assumption that the outcome works strictly 
via the exposure (i.e., up to 100% of the instruments may be invalid). The intercept term 
displays the overall pleiotropic effect, while the slope () coefficient displays a causal 
estimate under the assumption the pleiotropic effects of the SNP on the outcome are 
unrelated to the associations between the SNP and exposure (Corbin et al., 2016). Finally, I2 
statistics were calculated to determine heterogeneity between estimates from multiple 
genetic instruments, with higher numbers indicating greater heterogeneity which could 
indicate potential violations of the MR assumptions. Main findings are presented as IVW 
within the text. To avoid inference based simply on P-value thresholds, the direction and 
strength of effect for each association, together with the corresponding P-value, is presented 
(Sterne and Davey Smith, 2001). All analyses were conducted in R (version 3.3.2). 
Additionally, there was no direct overlap between samples. However, it is possible some 





Aggression and tobacco initiation. 
There was no clear evidence of an effect from genetic risk of aggression to tobacco 
use initiation (IVW<0.001, 95% CI -0.003 to 0.002, P = 0.810). While the MR-Egger analysis 
suggested there is some evidence of an effect on initiation, the effect estimates were 
inconsistent with those from the IVW and weighted median analyses (see Table 1 for full 
results). Findings were similar when looking at the effect from genetic risk of aggression to 
age at onset, with no clear evidence of an effect observed (IVW<0.001, 95% CI: 0.000 to 
0.001, P = 0.125). These findings were consistent when restricting to early childhood and 
late adolescence (see Table 1). There was moderate to high heterogeneity (see Table 1 for 
full results).  
 
 Inset Table 1 about here. 
 
ADHD and tobacco initiation. 
There was weak evidence of an association from genetic risk of ADHD to tobacco 
initiation (ORIVW 1.23, 95% CI 1.10 to 1.35, P = 0.016), and low heterogeneity (I2 = 29%). 
Although MR-Egger analysis indicated that there was some evidence of pleiotropy (ORIntercept 
1.06, 95% CI 1.03 to 1.09, P = 0.020), the bias-adjusted effect estimate remained consistent 
with that estimated using the IVW approach and suggested some weak evidence of a causal 
effect (ORSlope 1.40, 95% CI 1.10 to 1.78, P = 0.087). There was no clear evidence of an 
effect from genetic risk of ADHD to age of onset (see Table 2 for full results).  
 
 Insert Table 2 about here. 
 
Power calculation. 
 Post-hoc power calculations were conducted for our IVW analyses using an online 
Mendelian randomisation power calculation tool (https://sb452.shinyapps.io/power/) 
(Burgess, 2014). For the analysis investigating the effect of aggression with tobacco use 
initiation, using a genetic instrument that explains 1% of the variation in aggression and a 
sample containing 28% smoking cases, our study has 77% power to detect a causal effect of  
 = 0.1. Power was similar when looking at the effect of aggression on age at onset.  For the 
analysis investigating the effect of ADHD with tobacco use initiation, using a genetic 
instrument which explains 2% of the variation in ADHD and a sample containing 28% 
smoking cases, our study has 73% power to detect a causal effect of OR = 1.2. Power was 
similar when looking at the effect of ADHD on age at onset. 
 
Discussion 
Our results provide some evidence that genetic risk of childhood ADHD is causally 
related to increased risk of tobacco initiation; however, the causal estimate is relatively 
small. We found no clear evidence that genetic risk of childhood aggression is causally 
related to risk of tobacco initiation or age of onset. Therefore, the observational evidence 
relating to these associations (Kretschmer et al., 2014, Disney et al., 1999, Korhonen et al., 
2010, Rohde et al., 2004) may not be causal and may be due to environmental or 
confounding factors. 
Our findings with respect to genetic risk of ADHD and tobacco use initiation 
correspond with observational evidence (Breyer et al., 2014, Milberger et al., 1997, Kollins et 
al., 2005, Lambert and Hartsough, 1998), and the converging evidence from different MR 
methodologies provides further confidence in these findings. that these findings are robust. 
Neurobiological evidence also supports these causal associations (McClernon et al., 2008). 
However, as the MR-Egger analyses suggest some evidence of horizontal pleiotropy, the 
use of alternative causal inference methods relying on different assumptions (e.g. cross-
contextual comparisons across populations where confounding structures differ) will allow 
triangulation to determine whether these results do reflect true causal relationships (Gage et 
al., 2015, Munafo and Davey Smith, 2018).  
Within individuals with ADHD a hypoactive striatal dopaminergic system produces 
increased dopamine transporter within corticostrital circuits. This subsequently decreases 
dopamine tone and activation of presynaptic autoreceptors, resulting in exaggerated 
dopamine response to salient stimuli. As nicotine stimulates response in the striatum of 
smokers, nicotine-stimulated phasic dopamine releases may be more rewarding for 
individuals with ADHD (Dresel et al., 2000, Krause et al., 2002, Krause et al., 2003, Grace, 
2001). Therefore, this heighted reward response to dopamine in individuals with ADHD, may 
be responsible for reward and maintenance effects (Krause et al., 2000, Grace, 2001).  
These findings may help identify individuals particularly vulnerable to tobacco use 
behaviours, and therefore provide interventions from an early age. For example, previous 
evidence indicates that strong familial bonds and open communication within families and 
schools may serve as a protective factor, or help to delay adolescent substance initiation 
(McArdle et al., 2002, Kliewer and Murrelle, 2007, Farrell and White, 1998, Spoth et al., 
2004). 
There are a number of important strengths to this study. The use of Mendelian 
randomisation analysis strengthens causal inference and removes the possibility of reverse 
causation, confounding, and bias (Gage et al., 2015, Gage et al., 2016a). Furthermore, we 
integrated multiple methods with varying assumptions and strengths to formulate more 
robust causal inferences (Gage et al., 2015). The use of two-sample MR utilizes large 
sample sizes to provide the sufficient power required to detect small effects in complex 
phenotypes. However, there are also some limitations to consider. Unlike childhood 
aggression, which was a measurable trait of externalising disorders, ADHD was only 
measured as binary diagnosis. Previous evidence has suggested that particular traits of 
ADHD (i.e., inattention or impulsivity/hyperactivity) are more associated with the 
increased likelihood of tobacco initiation (McClernon et al., 2008). However, the current 
GWAS only examined ADHD diagnosis and not by individual symptomology. A GWAS of 
these individual traits has been conducted in adulthood (Mick et al., 2014), but sample sizes 
were small and summary statistics were unavailable. Finally, although we’ve conducted 
several analyses rather than correcting with a Bonferroni, we instead rely on consistent 
direction of effect rather than p values.   
Overall our results provided some evidence that there may be a causal association of 
genetic risk of ADHD on tobacco initiation, these results are in line with previous longitudinal 
and neurobiological evidence. However, there was no association of early aggressive 
behaviour on tobacco initiation, suggesting these observed associations may be a result of 
additional variables. Our results suggest that prevention efforts should target these risk 
groups, and explore whether interventions to reduce these behaviours influence subsequent 
tobacco use initiation. By identifying at-risk individuals, prevention behaviours such as 
strengthening familial bonds, open communication within families and schools, and early 
intervention education may help delay or prevent adolescent substance use initiation. 
(Steinberg et al., 1994, McArdle et al., 2002, Dishion et al., 2002, Kliewer and Murrelle, 
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